Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
August 5, 2020: Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
August 4, 2020: Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
July 27, 2020: Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team